Aerosolized Capreomycin for Inhibition of Pulmonary Tuberculosis
Description of Invention:
This technology involves the methods of reformulation of Capreomycin for the aerosol treatment of pulmonary tuberculosis.
Tuberculosis is a devastating lung disease that is highly infectious and easily transmitted, especially in areas of overcrowding such as prisons. Furthermore, underdeveloped countries with large populations living in close quarters maintain an endemic disease reservoir limiting the health and economic viability of the population. The WHO estimates that as many as 1/3 of the population may be infected. Current treatment requires the patient to take medication over an extended period of time, up to 12 months or more in some cases. This leads to clinical failure and the potential development of multi-drug resistant strains. Resistant strains of tuberculosis further tax the health care delivery as second line anti-tubercular therapies are more likely to have side effects yet still require long term adherence to therapy regimens.
The disclosed technology provides for the delivery of Capreomycin in an aerosol formulation. This provides for ease of delivery for in both first and second line tuberculosis regimens. Furthermore, the aerosol formulation does not require extensive training of health-care workers to administer the therapy, minimizing the need for added personnel in underdeveloped countries. This, along with the increased product stability will enhance patient adherence to therapy and the potential reduction of disease burden, both for the patient and the population.
Inventors:
Carl N. Kraus (NIAID) Clifton E. Barry III (NIAID) Bernard Doan (NIAID)
DHHS Reference No. E-286-2002/1 --
U.S. Provisional Application No. 60/497,892 filed 25 Aug 2003
DHHS Reference No. E-286-2002/2 --
PCT Application No. PCT/US03/28889 filed 12 Sep 2003, which published as WO 2004/024213 A3 on 25 Mar 2004
U.S. Patent Application No. 10/527,557 filed 10 Mar 2005
